R&D channel feed

Zai Lab bombs Phase IIa tri­al in atopic der­mati­tis, junks the pro­gram to shift re­sources to the pipeline

7 years ago

Out: NIH bud­get cuts. In: Alzheimer’s R&D as law­mak­ers boost pro­posed ’19 spend­ing to $2.3B

7 years ago

Hit by sur­prise set­back, As­traZeneca scram­bles to ex­plain why its two-in-one COPD in­haler was beat­en by GSK ri­val

7 years ago

No­var­tis just boast­ed of a big PhI­II PI3K suc­cess, but here’s why we should hold our ap­plause — for now

7 years ago

With Al­ler­gan's ri­val on the reg­u­la­to­ry ropes, Ab­b­Vie posts more promis­ing late-stage da­ta for elagolix

7 years ago

Jaun­dice drug for in­fants re­ject­ed by FDA, shak­ing up Mallinck­rodt's plans for new­ly-ac­quired stannso­porfin

7 years ago

FDA turns thumbs down on Al­ler­gan's op­ti­mistic case for uter­ine fi­broid drug as liv­er dam­age threat tor­pe­does ap­pli­ca­tion

7 years ago
Pharma

Shrink the pa­tient group, boost the ef­fi­ca­cy: Tonix says a retro look shows promise in se­lect PTSD group

7 years ago

Novo's new tri­al re­sults stoke block­buster hopes, with oral semaglu­tide scor­ing again in Phase II­Ia

7 years ago

Har­bour Bio­Med jumps in­to the crowd­ed PD-1/L1 race, look­ing to take a Chi­nese as­set glob­al as check­point pipeline bulges

7 years ago
China
Pharma

For­mer head of Chi­na's FDA boot­ed in wake of sear­ing vac­cine scan­dal as lead­ers im­pose 'se­vere pun­ish­men­t'

7 years ago
China

No more hands-off Roche su­per­vi­sion? Genen­tech brings out the axe, slash­ing 223 HQ staffers 'across de­part­ments'

7 years ago
Pharma

A 'high-risk, high-re­ward' ef­fort on NGF pain med fas­inum­ab by Re­gen­eron, Te­va clears a re­vised PhI­II -- se­ri­ous ques­tions linger

7 years ago

Bio­haven steps up big clin­i­cal plans for its re­for­mu­lat­ed ALS gener­ic — now al­so aimed at anx­i­ety

7 years ago

Look­ing to carve away mar­ket share from Gilead, Vi­iV and J&J score pos­i­tive PhI­II da­ta for a month­ly, 2-drug HIV in­jectable

7 years ago

Realm Ther­a­peu­tics shares crater — again — on a failed PhII atopic der­mati­tis study

7 years ago

Bay­er tar­gets COPD in a new dis­cov­ery al­liance with Hap­lo­gen, Evotec

7 years ago
Pharma

Mus­tang Bio ven­tures in­to gene ther­a­py, li­cens­ing 'bub­ble boy dis­ease' treat­ment from St. Jude

7 years ago
Pharma
Cell/Gene Tx

In back-to-back tri­al dis­as­ters, Gem­phire now says it shut­tered a tri­al af­ter see­ing pa­tients' fat­ty liv­er dis­ease get worse

7 years ago

Bio­gen's high-stakes Alzheimer's gam­ble is be­ing roast­ed by the ex­perts. Is the amy­loid be­ta the­o­ry dead?

7 years ago
Pharma

That BLA lit­tle Am­pio promised? That’s not go­ing any­where as FDA slap-down trig­gers an ug­ly rout

7 years ago

Paratek clears one last big hur­dle on the way to an FDA mar­ket­ing de­ci­sion for an­tibi­ot­ic

7 years ago

Re­genxBio ral­ly fades fast af­ter biotech re­ports set­backs, hos­pi­tal­iza­tion in gene ther­a­py study

7 years ago

First-in-hu­man stud­ies in sight, SQZ's cell ther­a­py tech wins over a di­verse group of in­vestors in $72M round

7 years ago
Discovery
First page Previous page 265266267268269270271 Next page Last page
A service from the Financial Times